Phospholipase Cβ3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain.

Authors :: Tie-Jun Sten Shi
Liu, Su-Xing Leslie
Hammarberg, Henrik
Watanabe, Masahiko
Xu, Zhi-Qing David
Hökfelt, Tomas
Source :: Proceedings of the National Academy of Sciences of the United States of America; 12/16/2008, Vol. 105 Issue 50, p20004-20008, 5p, 2 Color Photographs, 1 Black and White Photograph, 2 Graphs
Publication Year :: 2008
Abstract: Treatment of neuropathic pain is a major clinical problem. This study shows expression of phospholipase β3 (PLCβ3) in mouse and human ORG neurons, mainly in small ones and mostly with a nonpeptidergic phenotype. After spared nerve injury, the pain threshold was strongly reduced, and systemic treatment of such animals with the unselective PLC inhibitor U73122 caused a rapid and long-lasting (48-h) increase in pain threshold. Thus, inhibition of PLC may provide a way to treat neuropathic pain. [ABSTRACT FROM AUTHOR]

Subjects :: PHOSPHOLIPASES
NEUROGLIA
PAIN management
GALANIN
SPINAL cord
NEURONS
NEUROPEPTIDES
THERAPEUTICS

Language :: English
ISSN :: 00278424
Volume :: 105
Issue :: 50
Database :: Complementary Index
Journal :: Proceedings of the National Academy of Sciences of the United States of America
Publication Type :: Academic Journal
Accession number :: 35912328
Full Text :: https://doi.org/10.1073/pnas.0810899105

Full Text Access

Tools